DEK/CAN融合基因在髓系白血病中的研究进展

张海珍; 潘耀柱; 摆姣凤; 李文博; 白海

doi:10.13201/j.issn.1004-2806.2019.05.020

DEK/CAN融合基因在髓系白血病中的研究进展

- 中国人民解放军联勤保障部队第940医院(兰州, 730000)

详细信息

通讯作者: 潘耀柱,E-mail:panyaozhu@163.com

中图分类号: R733.71

收稿日期: 2018-12-26

Progress of DEK/CAN fusion gene in myeloid leukemia

More Information

Corresponding author: PAN Yaozhu, E-mail: panyaozhu@163.com

Received Date: 26 December 2018

摘要

- 急性髓系白血病 /
- 染色体易位 /
- 融合基因 /
- DEK/CAN /
- t (6 /
- 9)
Abstract: Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem/progenitor cells.AML is often associated with specific chromosomal translocations and associated abnormal fusion protein.t(6;9)-positive AML has been classified as an independent clinical entity due to its poor early onset and poor prognosis.The expression of DEK/CAN fusion protein is the marker of t(6;9)-AML.Because this chromosome translocation is extremely rare,the current understanding comes from a relatively small range of patients,so the knowledge of it is still very limited.
- acute myeloid leukemia /
- chromosome translocation /
- fusion gene /
- DEK/CAN /
- t(6 /
- 9)

HTML全文

参考文献(16)

[1]	Oancea C, Rüster B, Henschler R, et al.The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation[J].Leukemia, 2010, 24:1910-1909.
[2]	Ayatollahi H, Sadeghian MH, Naderi M, et al.Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia[J].J Res Med Sci, 2017, 22:54.
[3]	Qin H, Malek S, Cowell JK, et al.Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model[J].Oncogene, 2016, 35:5686-5691.
[4]	Zhou MH, Yang QM.NUP214 fusion genes in acute leukemia (Review)[J].Oncol Lett, 2014, 8:959-962.
[5]	Oancea C, Rüster B, Brill B, et al.STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML[J].Genes Cancer, 2014, 5:378-392.
[6]	Sitwala KV, Adams K, Markovitz DM.YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter[J].Oncogene, 2002, 21:8862-8870.
[7]	Ageberg M, Gullberg U, Lindmark A.The involvement of cellular proliferation status in the expression of the human proto-oncogene DEK[J].Haematologica, 2006, 91:268-269.
[8]	Saito S, Cigdem S, Okuwaki M, et al.Leukemia-associated Nup214 fusion proteins disturb the XPO1-mediated nuclear-cytoplasmic transport pathway and thereby the NF-κB signaling pathway[J].Mol Cell Biol, 2016, 36:1820-1835.
[9]	Saha AK, Kappes F, Mundade A, et al.Intercellular trafficking of the nuclear oncoprotein DEK[J].Proc Natl Acad Sci U S A, 2013, 110:6847-6852.
[10]	Sandén C, Ageberg M, Petersson J, et al.Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR[J].BMC Cancer, 2013, 13:440.
[11]	Garcon L, Libura M, Delabesse E, et al.DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification[J].Leukemia, 2005, 19:1338-1344.
[12]	Sandahl JD, Coenen EA, Forestier E, et al.(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia:an international study of 62 patients[J].Haematologica, 2014, 99:865-872.
[13]	刘田田, 杨文娟, 潘耀柱, 等.DEK/CAN基因阳性急性髓系白血病1例[J].中国肿瘤临床, 2016, 43(24):1114-1114.
[14]	李丽宁, 于书春, 白晓.伴dek/can融合基因阳性急性髓系白血病1例[J].检验医学与临床, 2013, 10(8):8-8.
[15]	杨光, 赵瑾, 石磊, 等.恶性血液病常见易位相关融合基因的检测[J].中国现代医生, 2009, 47(29):3-4.
[16]	Panagopoulos I, Gorunova L, Torkildsen S, et al.DEK-NUP214-fusion identified by RNA-sequencing of an acute myeloid leukemia with t(9;12)(q34;q15)[J].Cancer Genomics Proteomics, 2017, 14:437-443.